HC Wainwright Reiterates “Neutral” Rating for Sutro Biopharma (NASDAQ:STRO)
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat reports. They currently have a $2.00 price objective on the stock, down from their previous price objective of $12.00. HC Wainwright’s target price indicates a potential […]
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat reports. They currently have a $2.00 price objective on the stock, down from their previous price objective of $12.00. HC Wainwright’s target price indicates a potential […]
